Clinical medications development for opiate addiction: Focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention

Seminars in the Neurosciences

Volumn 9, Issue 3-4, 1997, Pages 158-172

  Herman, Barbara H ^a   O'Brien, Charles P ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ACAMPROSATE; ACETORPHAN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUSPIRONE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CLONIDINE; ELIPRODIL; ENKEPHALINASE INHIBITOR; GLUTAMATE RECEPTOR ANTAGONIST; LAMOTRIGINE; LESOPITRON; LOFEXIDINE; MEMANTINE; N (1 CARBOXY 2 PHENYLETHYL)PHENYLALANYL BETA ALANINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; NALMEFENE; NALTREXONE; NITRIC OXIDE SYNTHASE INHIBITOR; OPIATE ANTAGONIST; REMACEMIDE; SEROTONIN AGONIST;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGITATION; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DYSPHORIA; HEADACHE; HUMAN; HYPERTENSION; IRRITABILITY; MAJOR CLINICAL STUDY; META ANALYSIS; MUSCLE TONE; NAUSEA; OPIATE ADDICTION; PSYCHOSIS; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 0030664419     PISSN: 10445765     EISSN: None     Source Type: Journal    
DOI: 10.1006/smns.1997.0115     Document Type: Article

References (125)

1. 1. O'Brien, C. P. and McLellan, A. T. (1996) Myths about the treatment of addiction. Lancet 347, 237-240.
2. 2. Mendelson H., and Mello, N. K. (1996) Management of cocaine abuse and dependence. N. Eng. J. Med. 334, 965-972.
3. 3. McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E., and O'Brien, C. P. (1993) The effects of psychosocial services in substance abuse treatment. J. Am. Med. Assoc. 269, 1953-1959.
4. 4. Herman, B. H., Vocci, F., and Bridge, P. (1995) The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal: Medication development issues for opiate addiction. Neuropsychopharmacology 13, 269-294.
5. 5. Kreek, M. J. (1997) Clinical update of opioid agonist and partial agonist medications for the maintenance treatment of opiate addiction. Semin. Neurosci. 9.
6. 6. Kleber, H. D., and Riordan, C. E. (1982) The treatment of narcotic withdrawal: a historical review. J. Clin. Psychiatr. 43, 30-34.
7. 7. Mattick, R., and Hall, W. (1996) Are detoxification programmes effective? Lancet 347, 97-100.
8. 8. Ball, J. C., and Ross, A. (1991) The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York.
9. 9. Nestler, E. J. (1997) Molecular mechanisms underlying opiate addiction: implications for medications development. Semin. Neurosci. 9.
10. 10. Aghajanian, G. K. (1982) Central noradrenergic neurons: a locus for the functional interplay between alpha-2-adrenoreceptors and opiate receptors. J. Clin. Psychiatr. 43, 20-24.
11. 11. Gold, M. S. (1993) Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine. Recent Advances in Addictive Disorders. Psychiatr. Clin. North Am. 16, 61-73.
12. 12. Roth, R. H., Elsworth, J. D., and Redmond, D. E. (1982) Clonidine suppression of noradrenergic hyperactivity during morphine withdrawal by clonidine: Biochemical studies in rodents and primates. J. Clin. Psychiatr. 43, 42-46.
13. 13. Jaffe, J. H. (1995) Pharmacological treatment of opioid dependence: current techniques and new findings. Psychiatr. Ann. 25, 369-375.
14. 14. Aston-Jones, G., Shiekhattar, R., Akaoka, H., Rajkowski, and Kubiak, P. (1993) Opiates influence locus coeruleus neurons by potent indirect and direct actions. In The Neurobiology of Opiates (R. P. Hammer, Ed.), pp. 175-202. CRC Press, Boca Raton.
15. 15. Gold, M. S., Redmond, D. E., and Kleber, H. D. (1978) Clonidine blocks acute opiate withdrawal symptoms. Lancet 1, 599-601.
16. 16. Gold, M. S., Pottash, A. C., Sweeney, D. R., and Kleber, H. D. (1980) Opiate withdrawal using clonidine: A safe, effective, and rapid nonopiate treatment. JAMA 243, 343-346.
17. 17. Charney, D. S., Sternberg, D. E., Kleber, H. D., Heninger, G. R., and Redmond, D. (1981) The clinical use of clonidine in abrupt withdrawal from methadone. Arch. Gen. Psychiatr. 38, 1273-1277.
18. 18. Uhde, T. W., Redmond, D. E., and Kleber, H. D. (1980) Clonidine suppresses the opiate abstinence syndrome without clonidine-withdrawal symptoms: A blind inpatient study. Psychiatr. Res. 2, 37-47.
19. 19. Jasinski, D. R., Johnson, R. E., and Kocher, T. W. (1985) Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch. Gen. Psychiatr. 42, 1063-1066.
20. 20. Ghodse, H., Myles, J., and Smith, S. E. (1994) Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. Br. J. Psychiatr. 165, 370-374.
21. 21. Kahn, A., Mumford, J. P., Ash Rogers, G., and Beckford, H. (1997) Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 44, 57-61.
22. 22. Washton, A. M., and Resnick, R. B. (1981) Clonidine in opiate withdrawal: Review and appraisal of clinical findings. Pharmacotherapy 1, 140-146.
23. 23. Riordan, C. E., and Kleber, H. D. (1980) Rapid opiate detoxification with clonidine and naloxone. Lancet 1, 1079-1080.
24. 24. Charney, D. S., Riordan, C. E., Kleber, H. D., Murburg, M., Braverman, P., Sternberg, D. E., Heninger, G. R., and Redmond, E. (1982) Clonidine and naltrexone: A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Arch. Gen. Psychiatr. 39, 1327-1332.
25. 25. Charney, D. S., Heninger, G., and Kleber, H. D. (1986) The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am. J. Psychiatr. 143, 831-837.
26. 26. Gerra, G., Marcato, A., Caccavari, R., Fontanesi, B., Delsignore, R., Fertonani-, G., Avanzini, P., Rustichelli, P., and Passeri, M. (1995) Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J. Subst. Abuse Treat. 12, 35-41.
27. 27. Kleber, H. D., Topazian, M., Gaspari, J., Riordan, C. E., and Kosten, T. (1987) Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am. J. Drug Alcohol Abuse 13, 1-17.
28. 28. Marjamäki, A., Luomala, K., Ala-Uotila, S., and Scheinen, M. (1993) Use of recombinant human alpha-2-adrenoreceptors to characterize subtype selectivity of antagonist binding. Eur. J. Pharmacol. 246, 219-226.
29. 3H]RX821001 radio ligand binding: Computer modeling reveals that guanfacine is an alpha-2A-selective compound. Eur. J. Pharmacol. 202, 235-243.
30. 30. Arnsten, A. F. T., Cai, J. X., and Goldman-Rakic, P. S. (1988) The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive adverse effects: Evidence for alpha-2 receptor subtypes. J. Neurosci. 8, 4287-4298.
31. 31. Shearman, G. T., Lal, H., and Ursillo, R. C. (1980) Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharm. Biochem. Behav. 12, 573-575.
32. 32. Gold, M. S., Pottash, A. C., Sweeney, D. R., Extein, I., and Annitto, W. J. (1981) Opiate detoxification with lofexidine. Drug Alcohol Depend. 8, 307-315.
33. 33. Washton, A. M., and Resnick, R. B. (1982) Lofexidine in abrupt methadone withdrawal. Psychopharmacol. Bull. 18, 220-221.
34. 34. Washton, A. M., Resnick, R. B., and Geyer, G. (1983) Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects. J. Clin. Psychiatr. 44, 335-337.
35. 35. Beam, J., Gossop, M., and Strang, J. (1996) Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend. 43, 87-91.
36. 36. Gabilondo, A. M., Meana, J. J., Barturen, F., Sastre, M., and Garcia-Sevilla, J. A. (1994) Mu-opioid receptor and alpha 2-adrenoreceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacol. Berlin 115, 135-140.
37. 37. Gerra, G., Caccavari, R., Fontanesi, B., Delsignore, R., Fertonani-Affini, G., Marcato, A., Maestri, D., Avanzini, P., Perna, G., and Brambilla, F. (1994) Alpha-2-adrenoreceptor sensitivity in heroin addicts with and without previous attention deficit disorder/ hyperactivity and conduct disorder. Neuropsychobiology 30, 15-19.
38. 38. Inturrisi, C. E. (1997) Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence. Semin. Neurosci. 9.
39. 39. Haigler, H. J. (1994) NMDA receptor antagonists: neurotoxicity evaluation. Psychopharmacol. Bull. 30, 525.
40. 40. Auer, R. N., and Coulter, K. C. (1994) The nature and time course of neuronal vacuolation induced by the NMDA antagonist MK-801. Acta. Neuropathol. (Berlin) 87, 1-7.
41. 41. Olney, J. W., Labruyere, J., and Price, M. T. (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360-1362.
42. 42. Rasmussen, K., Fuller, R. W., Stockton, M. E., Perry, K. W., Swinford, R. M., and Ornstein, P. L. (1991) NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol. 197, 9-16.
43. 43. Koek, W., and Colpaert, F. C. (1990) Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252, 349-357.
44. 44. Herrling, P. L. (1994) D-CPPene (SDZ EAA 494), A competitive NMDA antagonist: results from animal models and first results in humans. Neuropsychopharmacology 10 (No 3S/Part 1): 591S.
45. 45. Vaupel, D. B., Kimes, A. S., and London, E. D. (1995) Nitric oxide synthase inhibitors: Preclinical studies of potential use for treatment of opioid withdrawal. Neuropsychopharmacology 13, 315-322.
46. 46. Chen, H., Pellegrini, J., Aggarwal, S., et al. (1992) Open channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12, 4427-4436.
47. 47. McQuay, H. J., Carroll, D., Jadad, A., Glynn, C. J., Jack, T., Moore, R. A., and Wiffen, P. J. (1994) Dextromethorphan for the treatment of neuropathic pain: A double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 59, 127-133.
48. 48. Nelson, K. A., Park, K. M., Robinovitz, E., Tsigos, C., and Max, M. B. (1997) High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology, 48, 1212-1218.
49. 49. Koyuncuoglu, M., and Saydam, B. (1990) The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with chlorpromazine. Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 147-152.
50. 50. Rosen, M. I., McMahon, T. J., Woods, S. W., Pearsall, H. R., and Kosten, T. R. (1996a) A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur. J. Pharmacol. 307, 251-257.
51. 51. Rosen, M. I., Hameedi, F. A., Pearsall, H. R., and Kosten, T. R. (1996b) The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Abstracts for The College on Problems of Drug Dependence, 58th Annual Scientific Meeting, June 22-27, p. 117, San Juan, Puerto Rico.
52. 52. Childress, A. R., Ehrman, R., Roohsenow, D. J., Robbins, S. J., and O'Brien, C. P. (1992) Classically conditioned factors in drug dependence. In Substance Abuse: A Comprehensive Textbook. (W. Lowinson, W. Luiz, R. B. Millman, J. G. Langard, Eds.), pp. 56-69. Williams & Wilkins, Baltimore.
53. 53. Pulvirenti, L., Balducci, C., and Koob, G. F. (1997) Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur. J. Pharmacol., 321, 279-283.
54. 54. Przegalinski, E., Tatarczynska, E., Deren-Wesolek, A., and Chojnacka-Wojcik, E. (1996) Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharm. Biochem. Behav. 54, 73-77.
55. 55. Popik, P., and Skolnick, P. (1996) The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53, 791-797.
56. 56. Zeise, M. L., Kasparov, V., Capogna, M., and Zieglgänsberger, W. (1993) Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: Possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 231, 47-51.
57. 57. Sass, H., Soyka, M., Mann, K., and Zieglgänsberger, W. (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatr. 53, 673-680.
58. 58. Litten, R. Z., Allen, J., and Fertig, J. (1996) Pharmacotherapies for alcohol problems: A review of research with focus on developments since 1991. Alcohol Clin. Exp. Res. 20, 859-876.
59. 59. Costall, B., Domeney, A. M., Farre, A. J., Kelly, M. E., Martinez, L., and Naylor, R. J. (1992) Profile or action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset. J. Pharmacol. Exp. Ther. 262, 90-98.
60. 60. Herman, B. H., and Panksepp, J. (1981) Ascending endorphinergic inhibition of distress vocalization. Science 211, 1060-1062.
61. 61. Ratey, J., Sovner, R., Parks, A., and Roengtine, K. (1991) Buspirone treatment of aggression and anxiety in mentally retarded patients: A multiple-baseline, placebo lead-in study. J. Clin. Psychiatr. 52, 159-162.
62. 62. Delle-Chiaie, R., Pancheri, P., Casacchia, M., Stratta, P., Kotzalidis, G. D., and Zibellini, M. (1995) Assessment of the efficacy of buspirone in patients affects by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: A placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 15, 12-19.
63. 63. O'Hanlon, J. F. (1991) Review of buspirone's effects on human performance and related variables. Eur. Neuropsychopharmacol. 1, 489-501.
64. 64. Aceto, M. D., Bowman, E. R., Harris, L. S., and May, E. L. (1992) Dependence studies of new compounds in the rhesus monkey and mouse (1991). Problems of Drug Dependence 1991. Proceedings of the 53rd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph 119 (L. Harris, Ed), pp. 554-555, Rockville, MD.
65. 65. Balster, R. L. (1990) Abuse potential of buspirone and related drugs. J. Clin. Psychopharmacol. 10 (3 Suppl): 31S-37S.
66. 66. Batki, S. L. (1990) Buspirone in drug users with AIDS or AIDS-related complex. J. Clin. Psychopharmacol. 10, 111S-115S.
67. 67. Curzon, G. (1991) Effects of tryptophan and of 5-hydroxytryptamine receptor subtype agonists on feeding. Adv. Exp. Med. Biol. 294, 377-388.
68. 68. Kranzler, H. R. (1996) Evaluation and treatment of anxiety symptoms and disorders in alcoholics. J. Clin. Psychiatr. 57 (Suppl 7): 12-21.
69. 69. Knapp, D. J., Benjamin, D., and Pohorecky, L. A. (1992) Effects of gepirone on ethanol consumption, exploratory behavior, and motor performance in rats. Drug Dev. Res. 26, 319-341.
70. 1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increases ethanol intake. Psychopharmacology 115, 173-179.
71. 71. Tollefson, G. D., Montague-Clouse, J., and Tollefson, S. L. (1992) Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J. Clin. Psychopharmacol. 12, 19-26.
72. 72. Cinciripini, P. M., Lapitsky, L., Seay, S., Wallfisch, A., Meyer, W. J. 3rd, and Van-Vunakis, H. (1995) A placebo-controlled evaluation of the effects of buspirone on smoking cessation: Differences between high-and low-anxiety smokers. J. Clin. Psychopharmacol. 15, 182-191.
73. 73. Maremmani, I., Zolesi, O., Daini, L., Castrogiovanni, P., and Tagliamonte A. (1995) Fluoxetine improves outcome in addicted patients treated with opioid antagonists. Am. J. Addictions 4, 267-271.
74. 74. Murphy, J. M., Waller, M. B., and Gatto, G. J. (1988) Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol-preferring P line of rats. Alcohol 5, 283-286.
75. 75. Hollister, L. (1978) Clinical evaluation of naltrexone treatment of opiate-dependent individuals: Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch. Gen. Psychiatr. 35, 335-341.
76. 76. Stanfa, L., Dickenson, A., Xu, X.-J., and Wiesenfeld-Hallin, Z. (1994) Cholecystokinin and morphine analgesia: variations on a theme. TiPS 15, 65-66.
77. 77. Faris, P. L., Komisaruk, B., Watkins, L. R., and Mayer, D. J. (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219, 310-312.
78. 78. Dourish, C. T., Hawley, D., and Iversen, S. D. (1988) Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur. J. Pharmacol. 147, 469-472.
79. 79. Dourish, C. T., O'Neill, M. F., Coughlan, J., Kitchener, S. J., Hawley, D., and Iversen, S. D. (1990) The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176, 35-44.
80. 80. Watkins, L. R., Kinshenk, I. B., and Mayer, D. J. (1984) Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224, 395-396.
81. 81. Wiesenfeld-Hallin, Z., Xu, X.-J., Hughes, J., Horwell, D. C., and Hökfelt, T. (1990) PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl. Acad. Sci. USA 87, 7105-7109.
82. 82. Xu, X.-J., Hoffman, O., and Wiesenfeld-Hallin, Z. (1996) L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: Electrophysiological and behavioural studies. Neuropeptides 30, 203-206.
83. 83. O'Neill, M. F., Dourish, C. T., Tye, S. J., and Iversen, S. D. (1990) Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey. Brain Res. 534, 287-290.
84. B receptor antagonists L-365,260. Eur. J. Pharmacol. 234, 147-152.
85. 85. Panerai, A. E., Rovati, L. C., Cocco, E., Sacerdote, P., and Mantegazza, P. (1987) Dissociation of tolerance and dependence to morphine: A possible role of cholecystokinin. Brain Res. 410, 52-60.
86. 86. Barber, N. S., Dourish, C. T., and Hill, D. R. (1989) The role of CCK caerulein, and CCK antagonists in nociception. Pain 39, 307-328.
87. 87. Maldonado, R., Valverde, O., Derrien, M., Tejedor-Real, P., and Roques, B. P. (1994) Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Pharmacol. Biochem. Behav. 48, 363-369.
88. 88. Hoffmann, O., and Wiesenfeld-Hallin, Z. (1994) The CCK-B receptor antagonist CI 988 reverses tolerance to morphine in rats. NeuroReport 5, 2565-2568.
89. 89. Tiseo, P. J., and Inturrisi, C. E. (1993) Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264, 1090-1096.
90. 90. Hendrie, C. A., Neill, J. C., Shepherd, J. K., and Dourish, C. T. (1993) The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol. Behav. 54, 689-693.
91. 91. Powell, K. R., and Barrett, J. E. (1991) Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19, 75-80.
92. 92. Bradwejn, J., Koszycki, D., Couëtoux du Tertre, A., van Megen, H., den Boer, J., Westenberg, H., and Annable, L. (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatr. 51, 486-493.
93. 93. Kramer, M. S., Cutler, N. R., Ballenger, J. C., Patterson, W. M., Mendels, J., Chenault, A., Shrivastava, R., Matzura-Wolfe, D., Lines, C., and Reines, S. (1995) A placebo-controlled trial of L-365,260, a CCKB antagonist in panic disorder. Biol. Psychiatr. 37, 462-466.
94. 94. Tokar, J. T., Brunse, A. J., Stefflre, V. J., Sodergren, J. A., and Napior, D. A. (1975) Determining what heroin means to heroin addicts. Dis. Nervous System 36, 77-81.
95. 95. Livingstone, S. J., Jewell, R. D. E., Rooney, K. F., et al. (1988) Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. Psychopharmacology 94, 540-544.
96. 96. Hartmann, F., Poirier, M.-F., Bourdel, M.-C., Loo, H., Lecomte, J.-M., and Schwartz, J.-C. (1991) Comparison of acetorphan with clonidine for opiate withdrawal symptoms. Am. J. Psychiatr. 148, 627-629.
97. 97. Roge, J., Baumer, P., Berard, H., Schwartz, J. C., and Lecomte, J. M. (1993) The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. Scand. J. Gastroenterol. 28, 352-354.
98. 98. Yaksh, T. L., Sabbe, M. B., Lucas, D., Mjanger, E., and Chipkin, R. E. (1991) Effects of [N-(L-(1-carboxy-2-phenyl)ethyl]-L-phenylalany1-β-alanine (SCH32615), a neutral endopeptidase (enkephalinase) inhibitor, on levels of enkephalin, encrypted enkephalins and substance P in cerebrospinal fluid and plasma or primates. J. Pharmacol. Exp. Ther. 256, 1033-1041.
99. 99. Roques, B. P., and Noble, F. (1995) Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. NIDA Res. Monogr. 147, 104-145.
100. 100. Fishman, J., Roffwarg, H., and Hellman, L. (1973) Disposition of naloxone in normal and narcotic-dependent men. J. Pharmacol. Exp. Ther. 187, 575-580.
101. 101. Resnick, R. B., Washton, A. M., Thomas, M. A., and Kestenbaum, R. S. (1978) Naltrexone in the treatment of opiate dependence. In The international challenge of drug abuse. NIDA research monograph no. 19. (R. C. Petersen, Ed.), pp. 321-332. National Institute on Drug Abuse, Rockville, MD.
102. 102. Resnick, R., Volavka, J., Freedman, A. M., and Thomas, M. (1974) Studies of EN-1639A (naltrexone): A new narcotic antagonist. Am. J. Psychiatr. 131, 646-650.
103. 103. O'Brien, C. P. (1978) Clinical pharmacology of narcotic antagonists. Annals of NY Academy of Sciences 311, 232-240.
104. 104. Martin, W. R., Jasinski, D., and Mansky, P. (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatr. 28, 784-791.
105. 105. Lee, M. C., Wagner, H. N., Tanada, S., Frost, J. J., Bice, A. N., and Dannals, R. F. (1988) Duration of occupancy of opiate receptors by naltrexone. J. Nuclear Med. 29, 1207-1211.
106. 106. Loimer, N., Lenz, K., Schmid, R., and Presslich, O. (1991) Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am. J. Psychiatr. 148, 933-935.
107. 107. Brewer, C., Rezae, H., and Bailey, C. (1988) Opioid withdrawal and naltrexone induction in 48-72 hours with minimal dropout, using a modification of the naltrexone-clonidine technique. Br. J. Psychiatr. 153, 340-343.
108. 108. Greenstein, R. A., Arndt, I. C., McClellan, A. T., O'Brien, C. P., and Evans, B. (1984) Naltrexone: a clinical perspective. J. Clin. Psychiatr. 45, 25-28.
109. 109. Washton, A. M., Pottash, A. C., and Gold, M. S. (1984) Naltrexone in addicted business executives and physicians. J. Clin. Psychiatr. 45, 39-41.
110. 110. Cornish, J., Metzger, D., Woody, G. E., Wilson, D., McLellan, A. T., Vandergrift, B., and O'Brien, C. P. (1997) Naltrexone pharmacotherapy for opioid dependent federal probationers. J. Substance Abuse Treatment, 14, 1-6.
111. 111. Gonzalez, J. P., and Brogden, R. N. (1988) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35, 192-213.
112. 112. Kranzler, H. (1996) Oral presentation - American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1996.
113. 113. Maggio, C. A., Presta, E., Bracco, E. F., et al (1985) Naltrexone and human eating behavior: A dose-ranging inpatient trial in moderately obese men. Brain Res. Bull. 14, 657-661.
114. 114. Hahn, E. F., Fishman, J., and Heilman, R. D. (1975) Narcotic antagonists. 4. Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists. J. Med. Chem. 18, 259-262.
115. 115. Dixon, R., Howes, J., Gentile, J., et al. (1986) Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. Clin. Pharmacol. Ther. 39, 49-53.
116. 116. Gal, T. J., DiFazio, C. A., and Dixon, R. (1986) Prolonged blockade of opioid effect with oral nalmefene. Clin. Pharmacol. Ther. 40, 537-542.
117. 117. Konieczko, K. M., Jones, J. G., Barrowcliffe, M. P., Jordan, C., and Altman, D. G. (1988) Antagonism of morphine-induced respiratory depression with nalmefene. Br. J. Anaesth. 61, 318-323.
118. 118. Glass, P. S. A., Jhaveri, R. M., and Smith, L. R. (1994) Comparison of potency and duration of action nalmefene and naloxone. Anesth. Analg. 78, 536-541.
119. 119. Barsan, W. G., Seger, D., Danzl, D. F., et al. (1989) Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures. Am. J. Emerg. Med. 7, 155-161.
120. 120. Fudala, P. J., Heishman, S. J., Henningfield, J. E., and Johnson, R. E. (1991) Human pharmacology and abuse potential of nalmefene. Clin. Pharmacol. Ther. 49, 300-306.
121. 121. Mason, B. J., Ritvo, E. C., Morgan, R. O., Salvato, F. R., Goldberg, G., Welch, B., and Mantero-Atienza, E. (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcoholism: Clin. Exp. Res. 18, 1162-1167.
122. 122. Ulm, R. R., Volpicelli, J. R., and Volpicelli, L. (1995) Opiates and alcohol self-administration in animals. J. Clin. Psychiatr. 56, 5-14.
123. 123. Volpicelli, J., Alterman, A., Hayashida, M., Muentz, L., and O'Brien, C. P. Naltrexone and the treatment of alcohol dependence. In Opioids, Bulimia and Alcoholism. (L. D. Reid, Ed.), pp. 195-214 Springer-Verlag. New York.
124. 124. Volpicelli, J. R., Alterman, A. I., Hayashida, M., and O'Brien, C. P. (1992) Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatr. 49, 876-880.
125. 125. O'Malley, S. S., Jaffe, A. J., Chang, G., Schottenfeld, R. S., Meyer, R. E., and Rounsaville, B. (1992) Naltrexone and coping skills therapy for alcohol dependence. Arch. Gen. Psychiatr. 49, 881-887.